Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Presbyterian Hospital Cancer Research
mi
from
Charlotte, NC
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Presbyterian Hospital Cancer Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Wisconsin
mi
from
Madison, WI
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Mayo Clinic
mi
from
Jacksonville, FL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
The Mayo Clinic
mi
from
Rochester, MN
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Unv. Of Nc At Chapel Hill
mi
from
Chapel Hill, NC
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Unv. Of Nc At Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Duke University Medical Center-Dept Of Medicine
mi
from
Durham, NC
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Duke University Medical Center-Dept Of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Ut Md Anderson Can Ctr.
mi
from
Houston, TX
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Ut Md Anderson Can Ctr.
mi
from
Houston, TX
Click here to add this to my saved trials
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated:  3/22/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated: 3/22/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated:  3/22/2017
The Mayo Clinic
mi
from
Rochester, MN
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated: 3/22/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated:  3/22/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated: 3/22/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated:  3/22/2017
Local Institution
mi
from
East Melbourne,
Multiple Ascending Dose of BMS-911543
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
Status: Enrolling
Updated: 3/22/2017
Local Institution
mi
from
East Melbourne,
Click here to add this to my saved trials
Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring
Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring
Status: Enrolling
Updated:  3/22/2017
UConn Health
mi
from
Farmington, CT
Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring
Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring
Status: Enrolling
Updated: 3/22/2017
UConn Health
mi
from
Farmington, CT
Click here to add this to my saved trials
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors
Status: Enrolling
Updated:  3/23/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors
Status: Enrolling
Updated: 3/23/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Microbiome Test for the Detection of Colorectal Polyps and Cancer
Metabiomics Neoplasia Clinical Research Study
Status: Enrolling
Updated:  3/27/2017
DC Endoscopy Center
mi
from
Washington,
Microbiome Test for the Detection of Colorectal Polyps and Cancer
Metabiomics Neoplasia Clinical Research Study
Status: Enrolling
Updated: 3/27/2017
DC Endoscopy Center
mi
from
Washington,
Click here to add this to my saved trials
Microbiome Test for the Detection of Colorectal Polyps and Cancer
Metabiomics Neoplasia Clinical Research Study
Status: Enrolling
Updated:  3/27/2017
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
Microbiome Test for the Detection of Colorectal Polyps and Cancer
Metabiomics Neoplasia Clinical Research Study
Status: Enrolling
Updated: 3/27/2017
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Stereotactic Radiosurgery (SRS) for Multiple CNS Mets
Stereotactic Radiosurgery for Multiple (5+) CNS Metastases
Status: Enrolling
Updated:  3/27/2017
MD Anderson Cancer Center at Cooper
mi
from
Camden, NJ
Stereotactic Radiosurgery (SRS) for Multiple CNS Mets
Stereotactic Radiosurgery for Multiple (5+) CNS Metastases
Status: Enrolling
Updated: 3/27/2017
MD Anderson Cancer Center at Cooper
mi
from
Camden, NJ
Click here to add this to my saved trials
Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)
Acupuncture to Prevent Postoperative Paralytic Ileus
Status: Enrolling
Updated:  3/27/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)
Acupuncture to Prevent Postoperative Paralytic Ileus
Status: Enrolling
Updated: 3/27/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated:  3/28/2017
University of Washington Medical Center
mi
from
Seattle, WA
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated: 3/28/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated:  3/28/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated: 3/28/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated:  3/28/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy
Status: Enrolling
Updated: 3/28/2017
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
H Lee Moffitt Comprehensive Cancer Center
mi
from
Tampa, FL
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
H Lee Moffitt Comprehensive Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated:  3/28/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer
Status: Enrolling
Updated: 3/28/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Melphalan With BBBD in Treating Patients With Brain Malignancies
Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study
Status: Enrolling
Updated:  3/29/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Melphalan With BBBD in Treating Patients With Brain Malignancies
Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study
Status: Enrolling
Updated: 3/29/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy
Status: Enrolling
Updated:  3/30/2017
Dana-Farber Cancer Center
mi
from
Boston, MA
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy
Status: Enrolling
Updated: 3/30/2017
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy
Status: Enrolling
Updated:  3/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy
Status: Enrolling
Updated: 3/30/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  3/30/2017
University of Maryland School of Medicine
mi
from
Baltimore, MD
MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 3/30/2017
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated:  3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated: 3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Colorado Denver (CTRC)
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Colorado Denver (CTRC)
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Colorado Hospital
mi
from
Aurora, CO
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Massachusetts General Hospital Clinical Laboratory
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Massachusetts General Hospital Clinical Laboratory
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Dana Ferber Cancer institute
mi
from
Boston, MA
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Dana Ferber Cancer institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
Karmanos Cancer Center/Wayne State University
mi
from
Detroit, MI
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
Karmanos Cancer Center/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated:  4/3/2017
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
mi
from
Bologna,
A Trial In Patients With Advanced Cancer And Leukemia
A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Status: Enrolling
Updated: 4/3/2017
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
mi
from
Bologna,
Click here to add this to my saved trials
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated:  4/3/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)
Status: Enrolling
Updated: 4/3/2017
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
University of California at Los Angeles Dept of Onc
mi
from
Los Angeles, CA
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
University of California at Los Angeles Dept of Onc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
Memorial Sloan Kettering Cancer Center Oncology Dept
mi
from
NY, NY
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
Memorial Sloan Kettering Cancer Center Oncology Dept
mi
from
NY, NY
Click here to add this to my saved trials
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated:  4/3/2017
Array BioPharma Investigative Site
mi
from
Leuven,
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Status: Enrolling
Updated: 4/3/2017
Array BioPharma Investigative Site
mi
from
Leuven,
Click here to add this to my saved trials